Cardiomyocyte generation using stem cells and directly reprogrammed cells

Masaki Ieda, Keiichi Fukuda

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Cardiomyocytes are terminally differentiated cells with limited regenerative capacity in the adult heart, making cell replacement therapy an attractive option to repair injured hearts. Embryonic stem (ES) cells and induced pluripotent stem (iPS) cells are pluripotent and capable of infinite expansion in vitro, implicating them as ideal cell types for cell replacement therapy. During the past several years, significant advances in iPS cell generation technology, cardiac differentiation, and cell purification protocols were achieved for the development of stem cell-based heart therapies. The discovery of iPS cells has also sparked the novel idea of direct conversion of mature cell types into another cell type without passing through a pluripotent stem cell state. Functional cardiomyocytes could therefore be directly reprogrammed from differentiated somatic cells by transduction of the three cardiac transcription factors, Gata4, Mef2c, and Tbx5. Herein, we review the recent research achievements and discuss future challenges in stem cell-based cardiac generation and direct cardiac reprogramming technology for heart regeneration.

Original languageEnglish
Pages (from-to)1413-1423
Number of pages11
JournalFrontiers in Bioscience - Scholar
Volume4 S
Issue number4
Publication statusPublished - 2012 Jun 1

Fingerprint

Stem cells
Cardiac Myocytes
Stem Cells
Induced Pluripotent Stem Cells
Cell- and Tissue-Based Therapy
Technology
Pluripotent Stem Cells
Embryonic Stem Cells
Regeneration
Cell Differentiation
Transcription Factors
Purification
Repair
Research
Therapeutics

Keywords

  • Cardiac regeneration
  • Heart
  • Induced cardiomyocyte
  • Reprogramming
  • Review
  • Stem cell

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Microbiology(all)
  • Medicine(all)

Cite this

Cardiomyocyte generation using stem cells and directly reprogrammed cells. / Ieda, Masaki; Fukuda, Keiichi.

In: Frontiers in Bioscience - Scholar, Vol. 4 S, No. 4, 01.06.2012, p. 1413-1423.

Research output: Contribution to journalArticle

@article{70b3ff417da445eba74eb5e1386dee1c,
title = "Cardiomyocyte generation using stem cells and directly reprogrammed cells",
abstract = "Cardiomyocytes are terminally differentiated cells with limited regenerative capacity in the adult heart, making cell replacement therapy an attractive option to repair injured hearts. Embryonic stem (ES) cells and induced pluripotent stem (iPS) cells are pluripotent and capable of infinite expansion in vitro, implicating them as ideal cell types for cell replacement therapy. During the past several years, significant advances in iPS cell generation technology, cardiac differentiation, and cell purification protocols were achieved for the development of stem cell-based heart therapies. The discovery of iPS cells has also sparked the novel idea of direct conversion of mature cell types into another cell type without passing through a pluripotent stem cell state. Functional cardiomyocytes could therefore be directly reprogrammed from differentiated somatic cells by transduction of the three cardiac transcription factors, Gata4, Mef2c, and Tbx5. Herein, we review the recent research achievements and discuss future challenges in stem cell-based cardiac generation and direct cardiac reprogramming technology for heart regeneration.",
keywords = "Cardiac regeneration, Heart, Induced cardiomyocyte, Reprogramming, Review, Stem cell",
author = "Masaki Ieda and Keiichi Fukuda",
year = "2012",
month = "6",
day = "1",
language = "English",
volume = "4 S",
pages = "1413--1423",
journal = "Frontiers in Bioscience - Scholar",
issn = "1945-0516",
publisher = "Frontiers in Bioscience",
number = "4",

}

TY - JOUR

T1 - Cardiomyocyte generation using stem cells and directly reprogrammed cells

AU - Ieda, Masaki

AU - Fukuda, Keiichi

PY - 2012/6/1

Y1 - 2012/6/1

N2 - Cardiomyocytes are terminally differentiated cells with limited regenerative capacity in the adult heart, making cell replacement therapy an attractive option to repair injured hearts. Embryonic stem (ES) cells and induced pluripotent stem (iPS) cells are pluripotent and capable of infinite expansion in vitro, implicating them as ideal cell types for cell replacement therapy. During the past several years, significant advances in iPS cell generation technology, cardiac differentiation, and cell purification protocols were achieved for the development of stem cell-based heart therapies. The discovery of iPS cells has also sparked the novel idea of direct conversion of mature cell types into another cell type without passing through a pluripotent stem cell state. Functional cardiomyocytes could therefore be directly reprogrammed from differentiated somatic cells by transduction of the three cardiac transcription factors, Gata4, Mef2c, and Tbx5. Herein, we review the recent research achievements and discuss future challenges in stem cell-based cardiac generation and direct cardiac reprogramming technology for heart regeneration.

AB - Cardiomyocytes are terminally differentiated cells with limited regenerative capacity in the adult heart, making cell replacement therapy an attractive option to repair injured hearts. Embryonic stem (ES) cells and induced pluripotent stem (iPS) cells are pluripotent and capable of infinite expansion in vitro, implicating them as ideal cell types for cell replacement therapy. During the past several years, significant advances in iPS cell generation technology, cardiac differentiation, and cell purification protocols were achieved for the development of stem cell-based heart therapies. The discovery of iPS cells has also sparked the novel idea of direct conversion of mature cell types into another cell type without passing through a pluripotent stem cell state. Functional cardiomyocytes could therefore be directly reprogrammed from differentiated somatic cells by transduction of the three cardiac transcription factors, Gata4, Mef2c, and Tbx5. Herein, we review the recent research achievements and discuss future challenges in stem cell-based cardiac generation and direct cardiac reprogramming technology for heart regeneration.

KW - Cardiac regeneration

KW - Heart

KW - Induced cardiomyocyte

KW - Reprogramming

KW - Review

KW - Stem cell

UR - http://www.scopus.com/inward/record.url?scp=84869424041&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84869424041&partnerID=8YFLogxK

M3 - Article

C2 - 22652883

AN - SCOPUS:84869424041

VL - 4 S

SP - 1413

EP - 1423

JO - Frontiers in Bioscience - Scholar

JF - Frontiers in Bioscience - Scholar

SN - 1945-0516

IS - 4

ER -